Inventor · disambiguated record
Peter Ordentlich
Also filed as: ORDENTLICH PETER
8 granted patents·18 pending applications·51 citations·filing 2000–2024
83Inventor score
Files withSYNDAX PHARMACEUTICALS INC19SALK INST FOR BIOLOGICAL STUDI2BURKE KONRAD1GOODENOW ROBERT1MARTIN RICHARD1
Top patents by PatentIndex Score
26 records- 0188US6673587B1Histone deacetylase, and uses thereforSALK INST FOR BIOLOGICAL STUDI·Filed 2000·Granted Jan 6, 2004·30 cites·25 claims
- 0284US10226472B2Methods for the treatment of breast cancerGOODENOW ROBERT·Filed 2012·Granted Mar 12, 2019·14 cites·18 claims
- 0381US11397184B2Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2016·Granted Jul 26, 2022·2 cites·19 claims
- 0480US11324822B2Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Granted May 10, 2022·3 cites·24 claims
- 0576US2024398944A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0675US2025064925A1Method of treating cancer using a combination of entinostat and an anti-csf-1r antibodySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0774US2024288425A1Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0870US2023022573A1Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0968US2023061048A1Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1066US2010305167A1Administration of an Inhibitor of HDACSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1164US2025011441A1Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibodySYNDAX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1263US12000829B2Selection of patients for combination therapySYNDAX PHARMACEUTICALS INC·Filed 2019·Granted Jun 4, 2024·0 cites·18 claims
- 1361US8455489B2Substituted pyrimidine compositions and methods of useMARTIN RICHARD·Filed 2004·Granted Jun 4, 2013·1 cites·20 claims
- 1459US12168054B2Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibodySYNDAX PHARMACEUTICALS INC·Filed 2018·Granted Dec 17, 2024·0 cites·22 claims
- 1558US2009149511A1Administration of an Inhibitor of HDAC and an mTOR InhibitorSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1657US2013303575A1Administration of an inhibitor of hdacBURKE KONRAD·Filed 2013·Application pending·0 cites
- 1757US2011182888A1Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor ModulatorORDENTLICH PETER·Filed 2009·Application pending·0 cites
- 1856US7314747B1SMRT co-repressors, transcriptional co-repressors that interact with nuclear hormone receptorsSALK INST FOR BIOLOGICAL STUDI·Filed 2000·Granted Jan 1, 2008·1 cites·9 claims
- 1956US2008242648A1COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCERSYNDAX PHARMACEUTICALS INC A C·Filed 2007·Application pending·0 cites
- 2055US2024238291A1Combinations for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2151US2010267779A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2251US2010298270A1Novel Compounds and Methods of Using ThemSYNDAX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2349US2019343844A1Methods for the treatment of breast cancerSYNDAX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2446US2013150386A1Methods for the treatment of lung cancerSYNDAX PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2537US2018353602A1Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2635US2019290759A1Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancerSYNDAX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Ordentlich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →